Concepedia

Wangang Xie

WX

Statistics

Publications

21

Citations

4K

H-Index

17

Active since

2003

Affiliations

AbbVie (United States)(Current)

University of Connecticut

Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas

Amsterdam University Medical Centers

Medical University of Vienna

Wangang Xie is an author at AbbVie (United States) specializing in pharmacotherapy, antiviral therapy, and viral hepatitis.

Publications per year

2003–2024

21

Publications

21

Improving Marginal Likelihood Estimation for Bayesian Phylogenetic Model Selection

Wangang Xie, Paul O. Lewis, Yu Fan et al. · Systematic Biology · 2010 · 1.1K citations · Full text

, , +17

ABT-450/r–Ombitasvir and Dasabuvir with or without Ribavirin for HCV

Péter Ferenci, David Bernstein, Jacob Lalezari et al. · New England Journal of Medicine · 2014 · 695 citations · Full text

, , +16

Upadacitinib as induction and maintenance therapy for moderately to severely active ulcerative colitis: results from three phase 3, multicentre, double-blind, randomised trials

Silvio Danese, Séverine Vermeire, Wen Zhou et al. · The Lancet · 2022 · 597 citations · Full text

, , +10

An Interferon-free Antiviral Regimen for HCV after Liver Transplantation

Paul Y. Kwo, Parvez Mantry, Eoin Coakley et al. · New England Journal of Medicine · 2014 · 402 citations · Full text

, , +17

Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1

Kris V. Kowdley, Eric Lawitz, Fred Poordad et al. · New England Journal of Medicine · 2014 · 258 citations · Full text

, , +17

1–5 of 21